Back to top
more

Accuray (ARAY)

(Real Time Quote from BATS)

$2.04 USD

2.04
1,022,576

+0.01 (0.49%)

Updated Nov 7, 2024 12:32 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (63 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

The Rise of Robots in Surgery Puts Spotlight on These 3 Stocks

by Zacks Equity Research

A number of MedTech companies are currently attempting to gain ground within the robotics-aided healthcare market.

Accuray's (ARAY) CyberKnife Delivers Improved Patient Outcome

by Zacks Equity Research

Accuray's (ARAY) CyberKnife delivers stereotactic body radiation therapy in only five sessions.

Why Is Accuray (ARAY) Down 1% Since Last Earnings Report?

by Zacks Equity Research

Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why Investors Should Retain Accuray (ARAY) Stock Now

by Zacks Equity Research

Accuray (ARAY) slashes fiscal 2020 revenue guidance owing to tariffs in China.

Accuray (ARAY) Reports Loss in Q4, Revenues Beat Estimates

by Zacks Equity Research

Accuray (ARAY) expects fiscal 2020 revenues to be impacted by China tariffs.

Accuray (ARAY) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Accuray (ARAY) delivered earnings and revenue surprises of -166.67% and 1.14%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Accuray (ARAY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Accuray (ARAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AngioDynamics Divests NAMIC Portfolio to Medline Industries

by Zacks Equity Research

The NAMIC fluid management portfolio sale clears all of AngioDynamics' (ANGO) outstanding debt.

Varian's (VAR) Halcyon to Treat Patients at Japan's Hospital

by Zacks Equity Research

Varian's (VAR) Halcyon sees encouraging developments in recent times.

Accuray (ARAY) Q3 Earnings Top Estimates, Gross Orders Rise

by Zacks Equity Research

Solid demand for Accuray's (ARAY) Radixact, CyberKnife and TomoTherapy platforms continue to boost business.

Accuray (ARAY) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Accuray (ARAY) delivered earnings and revenue surprises of 75.00% and -0.76%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Accuray (ARAY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Accuray (ARAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why Investors Should Retain Accuray (ARAY) Stock Now

by Zacks Equity Research

Management at Accuray (ARAY) sees significant opportunities in China.

Varian Medical's (VAR) ProBeam Installed in China's HIMC

by Zacks Equity Research

Varian Medical (VAR) has seen some notable developments in its Proton Therapy business in recent times.

AngioDynamics' Latest FDA Approval to Boost Oncology Unit

by Zacks Equity Research

AngioDynamics' (ANGO) OARtrac is the first of its kind radiation dose monitoring platform.

Varian Medical (VAR) Collaborates With Korea-Based Hospital

by Zacks Equity Research

Varian Medical (VAR) has seen notable developments in Asia of late.

Intuitive Surgical da Vinci SP Gets FDA Nod, Prospects Bright

by Zacks Equity Research

Intuitive Surgical (ISRG) fortifies its foothold in the global robotic-surgery market.

Varian & Tata Trust Tie Up to Boost Radiotherapy in India

by Zacks Equity Research

Varian's (VAR) three-year deal with Tata Trust is likely to fortify its foothold in the Asia-Pacific radiotherapy space.

Why Is Accuray (ARAY) Up 17% Since Last Earnings Report?

by Zacks Equity Research

Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why Investors Should Retain Accuray (ARAY) Stock Now

by Zacks Equity Research

A series of software upgrades is likely to provide Accuray (ARAY) a competitive edge in the radiation-oncology space.

Varian Strong on Global Expansion and Proton Therapy Arm

by Zacks Equity Research

Varian's (VAR) strong presence in China instills optimism in the stock.

Accuray & China Isotope Collaborate to Sell Radiation Devices

by Zacks Equity Research

Management at Accuray (ARAY) sees bright prospects in China.

Accuray's (ARAY) Q2 Loss Narrows, Radixact Demand Shoots Up

by Zacks Equity Research

Demand for flagship Radixact & CyberKnife platforms aids Accuray's (ARAY) fiscal Q2 results.

Will Accuray (ARAY) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Accuray (ARAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Invest in Accuray (ARAY) Stock Now

by Zacks Equity Research

Accuray's (ARAY) benefits from growing adoption of non-surgical treatment options among cancer patients and increasing demand for its latest offerings.